Patient Notification Logo
Fran├žais


About the Patient Notification System
Ensuring Confidentiality
Maintaining registrant confidentiality was one of the primary considerations in developing the system. An advisory panel made up of representatives from patient groups, the FDA, and participating companies helped design the system to safeguard sensitive registrant information. To ensure confidentiality, the Patient Notification System is operated by Sedgwick, an independent organization that specializes in pharmaceutical notifications.

All registrant information will be held in strict confidence by Sedgwick



Free to Registrants
There is no fee to participate in the Patient Notification System. The system is funded by the participating companies and is free to all registrants.



Cooperative Effort Between Industry and Stakeholders
    Founding Partners:
  • Alpha-1 Foundation
  • Committee of Ten Thousand
  • Hemophilia Federation of America
  • Immune Deficiency Foundation
  • National Hemophilia Foundation
These stakeholders worked closely with the plasma protein therapeutics industry in designing the Patient Notification System in 1998.

The system is administered by PPTA and is supported and funded by all participating companies.

  • ADMA Biologics Inc.
  • Bayer Healthcare LLC
  • CSL Behring
  • CSL Behring Canada
  • Genentech, a member of the Roche Group
  • Grifols Therapeutics LLC
  • Kedrion Biopharma Inc.
  • Novo Nordisk
  • Octapharma USA Inc.
  • Octapharma Canada Inc.
  • Pfizer Inc.
  • Saol Therapeutics
  • Takeda

An advisory panel made up of patient groups, the FDA, and industry representatives provides input on the system and makes additional recommendations for future enhancements.



How the System Works
Anyone interested in participating registers with the Patient Notification System and provides general contact information, including their preferred method of notification. Registrants have the opportunity of being notified by email, telephone, text message or fax, whichever is most convenient for them. Please consider email or text message as your method of notification as both are instantaneous, trackable, and immediately accessible, even when away from home.

If a therapy is withdrawn or recalled, the company involved immediately contacts Sedgwick which then directly notifies the registrant. Each registrant will also receive a letter by first-class mail to ensure receipt of the information.

In addition, registrants can go online to www.PatientNotificationSystem.org or call a 24-hour, toll-free number 1-888-UPDATE-U (1-888-873-2838) for current information on therapy recalls or withdrawals. To maximize the usefulness of the system, it is important for registrants to keep accurate infusion logs and record the lot number, therapy name, and manufacturer for all therapies used.






The Patient Notification System is endorsed by the following patient groups:

  • Alpha-1 Foundation
  • GBS/CIDP Foundation
  • Hemophilia Federation of America
  • Immune Deficiency Foundation
  • National Hemophilia Foundation


Register Today!


© 2022